sever
acut
respiratori
syndrom
coronaviru
sarscov
caus
fatal
human
respiratori
diseas
patient
sar
hereaft
refer
sar
patient
display
characterist
acut
lung
injuri
ali
includ
diffus
alveolar
damag
dad
epitheli
necrosi
fibrin
hyalin
deposit
patient
die
sar
develop
acut
respiratori
distress
syndrom
ard
sever
form
ali
recent
outbreak
sever
acut
respiratori
infect
emerg
virus
includ
middl
eastern
respiratori
syndrom
cov
merscov
highli
pathogen
avian
influenza
virus
eg
highlight
need
character
mechan
respons
virusmedi
ali
ard
fundament
ard
acut
onset
lung
inflamm
intim
tie
monocyt
macrophag
polar
function
lung
macrophag
highli
plastic
heterogen
cell
resid
lung
interstitium
alveoli
recruit
upon
inflammatori
stimuli
inflammatori
monocyt
resid
tissu
macrophag
play
critic
role
initi
maintain
inflamm
newli
emerg
virus
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
eastern
respiratori
syndrom
cov
merscov
caus
fatal
acut
lung
injuri
ali
drive
hypercytokinemia
aggress
inflamm
mechan
remain
elus
sarscovmacaqu
model
determin
antispik
igg
sigg
product
infect
lung
caus
sever
ali
skew
inflammationresolv
respons
alveolar
macrophag
underw
function
polar
acut
infect
macaqu
demonstr
simultan
proinflammatori
woundheal
characterist
presenc
sigg
prior
viral
clearanc
howev
abrog
woundheal
respons
promot
product
proinflammatori
monocytemacrophag
recruit
accumul
critic
patient
eventu
die
sar
hereaft
refer
deceas
patient
display
similarli
accumul
pulmonari
proinflammatori
absenc
woundheal
macrophag
faster
neutral
antibodi
respons
sera
enhanc
sarscovinduc
product
human
monocytederiv
woundheal
macrophag
wherea
blockad
reduc
effect
find
reveal
mechan
respons
virusmedi
ali
defin
patholog
consequ
viral
specif
antibodi
respons
provid
potenti
target
treatment
sarscov
virusmedi
lung
injuri
acut
stage
ard
well
resolut
phage
inflamm
recoveri
ard
steadi
state
resid
macrophag
normal
quiescent
prevent
damag
alveoli
critic
involv
normal
tissu
homeostasi
tissu
injuri
infect
resid
macrophag
becom
activ
circul
monocyt
effici
recruit
site
injuri
inflammatori
monocytesmacrophag
imm
resid
macrophag
undergo
mark
phenotyp
function
chang
classifi
proinflammatori
classic
activ
inflammatoryresolv
altern
activ
woundheal
antiinflammatori
macrophag
continuum
macrophag
polar
exist
beyond
discret
categori
acut
infect
monocytesmacrophag
often
display
phenotyp
classic
activ
macrophag
cell
mediat
host
defens
virus
also
promot
lung
injuri
produc
nitric
oxid
ro
tnf
simultan
macrophag
may
becom
altern
activ
exert
antiinflammatori
function
regul
wound
heal
produc
matrix
metalloproteinas
mmp
growth
factor
antiinflammatori
cytokin
particularli
pathogen
inflammatori
stimulu
elimin
proinflammatori
macrophag
diminish
predomin
macrophag
popul
assum
woundheal
phenotyp
final
recoveri
stage
macrophag
show
regulatorysuppress
phenotyp
secret
increas
level
facilit
resolut
wound
heal
restor
homeostasi
woundheal
respons
well
organ
control
inflammatori
respons
resolv
quickli
normal
tissu
architectur
restor
disturb
woundheal
respons
lead
uncontrol
product
inflammatori
mediat
contribut
state
persist
injuri
patient
eventu
die
sar
hereaft
refer
deceas
patient
anim
model
extens
lung
damag
associ
high
initi
viral
load
increas
imm
accumul
lung
elev
serum
proinflammatori
cytokin
level
much
known
termin
phase
sar
littl
known
earli
immun
event
acut
phase
infect
studi
defin
macrophag
heterogen
function
acut
infect
ali
use
nonhuman
primat
patient
specimen
limit
factor
drive
hypercytokinemia
aggress
inflamm
remain
elus
sar
outbreak
hong
kong
patient
present
abnorm
chest
radiograph
approxim
onequart
individu
progress
ali
day
sar
patient
develop
ard
coincid
igg
seroconvers
detail
analysi
antibodi
respons
sarscov
spike
glycoprotein
report
anti
neutral
antibodi
nab
respons
develop
significantli
faster
deceas
patient
compar
recov
patient
onset
clinic
symptom
took
averag
day
recov
patient
reach
peak
nab
activ
oppos
day
deceas
patient
moreov
actual
nab
titer
significantli
higher
deceas
patient
compar
recov
patient
time
period
find
suggest
role
anti
antibodi
sarscovmedi
ali
acut
infect
consist
preexist
serum
antibodi
influenza
antigen
found
associ
wors
clinic
sever
poor
outcom
patient
influenza
pandem
moreov
multipl
vaccin
platform
viral
infect
appear
induc
sarscovspecif
immun
memori
enhanc
lung
inflamm
follow
homolog
challeng
mice
african
green
monkey
mechan
respons
immunopatholog
reaction
remain
elus
recent
studi
suggest
cell
play
crucial
role
protect
mice
lethal
sarscov
infect
enhanc
pulmonari
immunopatholog
vaccin
challeng
anim
reflect
inadequ
respons
role
virusspecif
antibodi
respons
sarscovinduc
lung
injuri
yet
clearli
defin
therefor
use
vaccin
antisigg
passiv
immun
strategi
evalu
effect
anti
antibodi
sarscovinduc
ali
chines
rhesu
monkey
macaca
mulatta
result
show
product
infect
lung
antisigg
caus
sever
ali
skew
inflammatori
resolv
respons
acut
infect
vaccineinduc
sspecif
immun
result
sever
ali
sarscov
infect
chines
macaqu
initi
compar
patholog
chang
lung
rhesu
macaqu
vaccin
modifi
vaccinia
ankara
mva
viru
encod
fulllength
sarscov
glycoprotein
adsmva
control
day
pathogen
sarscov
pumc
tissu
cultur
infecti
dose
tcid
challeng
three
healthi
macaqu
includ
control
sixteen
macaqu
im
immun
twice
anim
adsmva
anoth
anim
control
mva
adcmva
figur
vaccin
adsmva
induc
high
level
antisarscov
nab
macaqu
sera
ic
valu
rang
dilut
figur
none
macaqu
develop
fever
vaccin
normal
bodi
temperatur
ic
valu
sera
maintain
reciproc
serum
dilut
week
secondari
immun
time
anim
challeng
figur
viral
challeng
macaqu
develop
fever
day
inocul
dpi
rang
sera
control
vaccin
macaqu
show
increas
neutral
activ
dpi
indic
establish
infect
figur
sarscov
rna
readili
detect
oral
swab
control
macaqu
examin
multipl
time
point
use
realtim
revers
transcript
pcr
realtim
rtpcr
adsmvavaccin
macaqu
lower
nab
titer
dpi
figur
suggest
reduc
product
viral
infect
immun
macaqu
sspecif
immun
howev
histolog
examin
reveal
acut
dad
variou
degre
sever
adsmvavaccin
macaqu
dpi
wherea
control
macaqu
adcmva
group
show
minor
moder
inflamm
figur
better
character
patholog
chang
adopt
score
system
describ
sever
lung
damag
least
sever
sever
supplement
figur
supplement
materi
avail
onlin
articl
http
control
vaccin
group
macaqu
show
minor
inflamm
slight
septa
broaden
inflammatori
cell
infiltr
score
figur
supplement
figur
supplement
figur
two
macaqu
show
moder
inflamm
interstiti
mononuclear
inflammatori
infiltr
score
supplement
figur
supplement
figur
macaqu
show
typic
symptom
acut
dad
extens
exud
cell
infiltr
dpi
score
supplement
figur
adsmvavaccin
group
macaqu
show
typic
symptom
acut
dad
extens
exud
manycel
infiltr
alveolar
caviti
score
supplement
figur
supplement
figur
one
macaqu
show
sever
acut
dad
exud
hyalin
membran
format
along
alveoli
pneumocyt
desquam
damag
alveolu
fill
hemorrhag
inflammatori
cell
score
figur
one
macaqu
show
earli
symptom
acut
dad
score
supplement
figur
remain
macaqu
show
moder
inflamm
score
supplement
figur
comparison
lung
histopathlog
score
group
show
significantli
enhanc
lung
injuri
adsmvavaccin
group
dpi
compar
control
adcmva
group
suggest
sspecif
mvaspecif
immun
promot
ali
sarscov
infect
figur
moreov
moder
correl
lung
patholog
score
sera
nab
titer
dpi
figur
suggest
role
sspecif
antibodi
enhanc
sarscovmedi
lung
injuri
antisigg
induc
sever
lung
injuri
acut
sarscov
infect
previou
studi
inocul
chines
macaqu
sarscov
pumc
tcid
led
lower
respiratori
tract
infect
anim
within
day
howev
rapidli
clear
infect
lung
anim
n
exhibit
mild
lung
lesion
dpi
sever
lung
injuri
sarscovinfect
chines
macaqu
detect
dpi
determin
effect
anti
antibodi
extent
sarscovmedi
lung
injuri
adopt
transfer
mg
low
dose
mg
high
dose
purifi
antisigg
adsmvavaccin
unchalleng
macaqu
group
unvaccin
macaqu
n
via
iv
inject
challeng
recipi
sarscov
pumc
tcid
figur
control
anoth
macaqu
administ
mg
control
igg
cigg
deriv
adcmvavaccin
macaqu
sacrif
half
macaqu
group
dpi
avoid
potenti
disrupt
viru
infectioninduc
antibodi
nucleocapsid
protein
n
viral
protein
prior
induct
ali
typic
observ
remain
half
macaqu
group
sacrif
dpi
evalu
longterm
impact
figur
day
sera
macaqu
receiv
lowor
highdos
sigg
show
neutral
activ
ic
valu
rang
correspond
dose
sera
transfer
macaqu
receiv
cigg
fail
show
neutral
activ
figur
supplement
tabl
nab
titer
sera
macaqu
highdos
group
declin
steadili
dpi
macaqu
lowdos
control
group
display
increas
nab
titer
time
figur
suggest
activ
viral
replic
inde
sarscov
rna
detect
use
realtim
rtpcr
oral
swab
andor
viru
recov
lung
tissu
control
anim
anim
lowdos
group
anim
highdos
group
viral
rna
figur
supplement
tabl
suggest
reduc
viral
product
highdos
sigg
consist
find
control
adcmvavaccin
group
histopatholog
examin
lung
indic
minor
moder
inflamm
day
cigg
recipi
respect
contrast
sigg
recipi
exhibit
symptom
acut
dad
variou
degre
exud
hyalin
membran
format
hemorrhag
inflammatori
cell
within
alveolu
day
figur
e
supplement
tabl
note
despit
presenc
high
titer
sera
nab
chronic
stage
infect
figur
figur
cigg
control
figur
score
index
base
sever
lung
histopatholog
data
repres
mean
sem
valu
statist
analysi
undertaken
use
unpair
student
test
p
n
f
correl
lung
histopatholog
score
macaqu
sera
nab
titer
dpi
solid
line
denot
relationship
histopatholog
score
serum
neutral
activ
statist
analysi
perform
use
spearman
rank
correl
test
adcmva
vaccin
recipi
show
acut
dad
figur
figur
indic
timerestrict
role
sigg
mostli
caus
sever
ali
acut
infect
macaqu
therefor
conclud
despit
viral
suppress
presenc
sigg
acut
stage
sarscov
infect
caus
sever
ali
persist
late
stage
experiment
design
use
investig
influenc
sigg
sarscovinduc
lung
injuri
two
group
chines
rhesu
macaqu
n
subject
iv
inject
highdos
mg
lowdos
mg
purifi
sigg
adsmvavaccin
unchalleng
macaqu
control
anoth
macaqu
administ
mg
cigg
deriv
adcmvavaccin
macaqu
day
group
macaqu
challeng
sarscov
pumc
tcid
half
anim
group
sacrif
dpi
b
sera
macaqu
indic
time
point
test
capac
neutral
sarscov
pseudotyp
viru
c
detect
viral
rna
oral
swab
sarscov
rna
detect
nest
rtpcr
swab
one
highdos
siggtreat
macaqu
n
lowdos
siggtreat
macaqu
n
ciggtreat
macaqu
n
indic
time
point
left
axi
show
viral
rna
copi
number
per
millilit
swab
right
axi
show
serum
nab
titer
macaqu
dpi
highlight
shade
area
patholog
chang
lung
tissu
section
macaqu
stain
h
e
imag
show
symptom
acut
dad
exhibit
macaqu
receiv
highdos
lowdos
sigg
n
extens
exud
red
arrow
hyalin
membran
black
arrow
massiv
cell
infiltr
yellow
arrow
dpi
right
panel
show
minor
moder
inflamm
macaqu
receiv
cigg
slight
alveolar
septa
broaden
spars
monocyt
infiltr
dpi
e
histopatholog
score
highdos
lowdos
sigg
group
includ
lung
sampl
collect
dpi
compar
cigg
group
see
supplement
figur
score
index
base
sever
lung
histopatholog
determin
potenti
caus
siggenhanc
ali
measur
viral
infect
monocytesmacrophag
infiltr
lung
serum
cytokin
profil
dpi
previous
found
pulmonari
infect
chines
macaqu
could
rapidli
control
viral
rna
cell
detect
lung
anim
dpi
although
viral
nucleoproteinposit
np
lung
hilar
lymph
node
ln
lymphat
lung
drain
therefor
measur
viral
rna
cell
situ
hybrid
ish
well
np
signal
lung
hilar
ln
ihc
stain
evalu
actual
pulmonari
infect
macaqu
consist
result
viral
isol
supplement
tabl
viral
rna
detect
pneumocyt
macaqu
highdos
macaqu
lowdos
ciggtreat
macaqu
figur
supplement
tabl
suggest
reduc
product
infect
sigg
howev
np
antibodi
identifi
posit
signal
lung
hilar
ln
sigg
cigg
recipi
macaqu
healthi
control
figur
supplement
tabl
suggest
sigg
fail
prevent
sarscov
entri
sarscov
establish
lower
respiratori
tract
infect
challeng
anim
consist
previou
find
sarscovinocul
naiv
chines
macaqu
n
doubleimmunostain
np
antibodi
antibodi
specif
stage
macrophag
differenti
inflamm
reveal
signific
infiltr
imm
lung
cigg
recipi
consist
newli
infiltr
inflammatori
monocyt
macrophag
figur
supplement
figur
cell
greatli
exceed
popul
typic
gather
around
np
cell
form
cell
cluster
figur
show
associ
viral
infect
imm
infiltr
macaqu
compar
cigg
recipi
robust
signal
identifi
lung
sigg
recipi
figur
supplement
figur
suggest
enhanc
imm
infiltr
sigg
monocytesmacrophag
gather
around
np
cell
also
form
cluster
tissu
littl
np
signal
figur
suggest
infectioninduc
recruit
circul
continu
viral
clearanc
accumul
inflam
site
moreov
moreconcentr
signal
found
indic
alter
macrophag
function
respons
sigg
treatment
figur
consist
elev
serum
level
observ
macaqu
treat
highdos
sigg
dpi
supplement
figur
level
strongli
correl
antisarscov
nab
titer
supplement
figur
macrophagederiv
inflammatori
cytokin
import
initi
ali
result
therefor
suggest
sigg
like
alter
macrophag
function
respons
lung
acut
infect
result
increas
product
enhanc
ali
imm
infiltr
accumul
alveolar
monocytesmacrophag
assum
woundheal
function
earli
dpi
macaqu
treat
sigg
macrophag
activ
dynam
plastic
differ
monocytemacrophag
activ
statu
differ
special
critic
time
role
take
part
either
initi
mainten
resolut
inflamm
wellorgan
woundheal
respons
lead
time
resolut
inflamm
wherea
disturb
woundheal
respons
result
persist
inflamm
injuri
understand
siggcaus
excess
inflamm
defin
macrophag
heterogen
activ
statu
lung
lesion
cigg
n
sigg
recipi
n
dpi
three
healthi
macaqu
naiv
chines
macaqu
challeng
dose
sarscov
pumc
scarifi
dpi
previou
studi
includ
control
combin
macrophag
marker
subpopul
resid
macrophag
shown
lung
chines
rhesu
macaqu
steadi
state
previous
describ
interstiti
macrophag
im
figur
resid
alveolar
macrophag
am
express
low
level
marker
specif
macrophag
woundheal
respons
correspond
intrins
antiinflammatori
function
figur
lung
lesion
ciggtreat
naiv
macaqu
group
challeng
sarscov
pumc
imm
character
divid
subpopul
one
subpopul
recent
recruit
figur
like
im
larger
size
primarili
coexpress
supplement
figur
subpopul
singl
inflammatori
macrophag
differenti
newli
recruit
monocytesmacrophag
figur
supplement
figur
importantli
resid
am
differenti
cell
slight
increas
number
increas
size
stronger
importantli
stain
suggest
altern
activ
figur
strikingli
elev
level
express
detect
enlarg
well
macrophag
lung
ciggtreat
unvaccin
macaqu
compar
healthi
control
figur
gi
indic
mani
imm
activ
resid
am
assum
woundheal
function
infect
lung
within
day
infect
sigg
treatment
skew
woundheal
macrophag
respons
lung
acut
sarscov
infect
compar
macaqu
treat
sigg
number
imm
significantli
increas
sigg
recipi
figur
e
f
moreov
mani
recent
recruit
coexpress
supplement
figur
repres
newest
recruit
blood
monocyt
result
enhanc
monocyt
infiltr
sigg
importantli
major
imm
coexpress
supplement
figur
suggest
chang
function
subpopul
sigg
moreov
resid
macrophag
lung
sigg
recipi
longer
express
surround
mani
imm
figur
suggest
loss
woundheal
function
role
recruit
blood
monocyt
consist
siggtreat
macaqu
display
loss
high
express
macrophag
subpopul
figur
g
h
j
favor
macrophag
accumul
site
injuri
import
develop
persist
inflamm
ali
therefor
conclud
am
underw
phenotyp
function
chang
acut
infect
lung
mani
monocytesmacrophag
assum
woundheal
function
inflamm
resolut
presenc
sigg
skew
woundheal
respons
lead
uncontrol
inflamm
tissu
injuri
onset
antibodi
respons
prior
viral
clearanc
associ
abrog
wound
heal
respons
increas
imm
lung
infiltr
unvaccin
chines
rhesu
macaqu
understand
mechan
underli
timerestrict
role
sigg
promot
ali
conduct
tempor
analysi
product
viral
infect
antibodi
respons
macrophag
function
chang
unvaccin
chines
macaqu
first
week
infect
naiv
macaqu
challeng
tcid
sarscov
pumc
sacrif
dpi
macaquesgroup
figur
success
lower
respiratori
tract
infect
confirm
detect
viral
np
use
ihc
stain
lung
macaqu
viral
rna
alveolar
pneumocyt
primarili
found
dpi
macaqu
infrequ
dpi
macaqu
figur
supplement
tabl
dpi
viral
rna
detect
lung
macaqu
suggest
product
infect
figur
b
c
scatter
np
cell
found
figur
neither
np
viral
rna
found
lung
swab
suggest
clearanc
product
viral
pulmonari
infect
macaqu
figur
supplement
tabl
serum
nab
observ
dpi
dpi
macaqu
supplement
tabl
figur
agreement
find
cigg
group
tempor
analysi
macrophag
heterogen
reveal
significantli
increas
number
imm
viral
rna
lung
dpi
figur
right
imag
imm
diminish
dpi
macaqu
figur
becam
nearli
complet
absent
dpi
macaqu
without
product
pulmonari
viral
infect
macaqu
figur
indic
inflammatori
respons
resolv
day
follow
control
product
infect
critic
woundheal
macrophag
observ
lung
macaqu
dpi
despit
product
pulmonari
viral
infect
macaqu
figur
contrast
macaqu
serum
nab
product
viru
infect
lung
display
significantli
enhanc
proinflammatori
macrophag
respons
reduc
inflammatoryresolv
macrophag
figur
observ
macaqu
product
viral
infect
undetect
nab
respons
macaqu
detect
nab
undetect
viral
replic
figur
supplement
tabl
therefor
persist
viral
replic
concomit
nab
detect
associ
increas
imm
lung
infiltr
reduc
woundheal
macrophag
number
sigg
modifi
function
respons
altern
classic
activ
macrophag
sarscov
infect
determin
whether
sigg
skew
woundheal
respons
modifi
woundheal
macrophag
function
respons
sarscov
infect
treat
vitropolar
altern
activ
human
monocytederiv
macrophag
mdm
hour
sarscov
pseudoviru
heatinactiv
sera
highdos
siggtreat
macaqu
sigg
sera
collect
dpi
measur
concentr
inflammatori
cytokin
cell
cultur
supernat
includ
sera
cigg
recipi
healthi
macaqu
includ
control
vitropolar
classic
activ
mdm
also
studi
compar
altern
activ
mdm
parallel
consist
previou
report
unstimul
classic
activ
mdm
produc
high
level
altern
activ
mdm
produc
minim
level
cytokin
figur
addit
sarscov
pseudoviru
induc
product
altern
activ
mdm
level
compar
found
unstimul
classic
activ
mdm
well
lowlevel
product
figur
contrast
sarscov
pseudoviru
caus
less
increas
secret
cytokin
secret
classic
activ
mdm
figur
strikingli
none
sera
sampl
induc
cytokin
product
administ
mdm
alon
panel
b
f
b
show
subpopul
steadi
state
includ
interstiti
macrophag
im
yellow
arrow
resid
alveolar
macrophag
lo
lo
white
arrow
c
show
presenc
altern
activ
resid
accumul
imm
cigg
group
altern
activ
am
hi
hi
white
arrow
im
c
yellow
arrow
imm
includ
newli
infiltr
monocyt
macrophag
c
green
arrow
inflammatori
macrophag
green
arrow
e
f
show
significantli
increas
number
imm
decreas
number
altern
activ
macrophag
sigg
group
imm
includ
newli
infiltr
monocytesmacrophag
e
green
arrow
inflammatori
macrophag
green
arrow
f
upper
panel
green
arrow
f
lower
panel
resid
am
longer
express
blue
arrow
f
upper
panel
gj
express
macrophag
lung
section
doubleimmunostain
antibodi
tritc
fitc
g
show
low
express
level
im
am
healthi
macaqu
h
show
increas
express
cigg
group
white
arrow
increas
sigg
group
blue
arrow
j
show
number
monocytesmacrophag
group
field
administr
sigg
sera
caus
dosedepend
increas
product
inflammatori
cytokin
sarscovstimul
altern
activ
mdm
result
greater
increas
increas
increas
figur
e
enhanc
howev
observ
sigg
sera
replac
sera
cigg
recipi
healthi
macaqu
figur
f
g
h
suggest
sigg
sera
compon
enhanc
sarscovstimul
cytokin
product
altern
activ
mdm
administr
sigg
sera
effect
cytokin
product
sarscovtr
classic
activ
mdm
figur
j
k
indic
sigg
modul
virusmedi
classic
activ
macrophag
function
respons
key
cytokin
regul
monocytesmacrophag
migrat
promot
neutrophil
infiltr
promot
persist
inflamm
injuri
result
suggest
respons
sarscov
infect
woundheal
macrophag
produc
low
amount
recruit
neutrophil
blood
monocyt
wherea
presenc
viral
rna
tritc
type
pneumocyt
fitc
found
dpi
n
dpi
n
c
viral
rna
swab
lung
homogen
dpi
sarscov
rna
detect
use
nest
rtpcr
swab
macaqu
lung
homogen
macaqu
viral
antigen
inflammatori
infiltr
lung
dpi
section
stain
sarscov
np
red
nucleu
blue
ihc
show
np
signal
macrophagelik
cell
red
arrow
type
pneumocyt
blue
arrow
substanti
inflammatori
infiltr
observ
green
arrow
e
serum
neutral
activ
serum
neutral
activ
detect
macaqu
dpi
fi
decreas
woundheal
respons
macaqu
product
pulmonari
viral
infect
serum
neutral
activ
section
doubleimmunostain
tritc
fitc
tripl
stain
cyan
fitc
tritc
figur
show
woundheal
respons
took
place
within
dpi
altern
activ
monocytesmacrophag
white
arrow
imm
green
arrow
coexist
lung
f
viral
clearanc
imm
diminish
dpi
g
homeostasi
restor
dpi
h
pulmonari
viral
infect
persist
imm
green
arrow
infiltr
accumul
enhanc
woundheal
macrophag
reduc
macaqu
faster
nab
respons
sigg
result
increas
product
woundheal
macrophag
lead
significantli
enhanc
persist
monocyt
infiltr
tissu
injuri
critic
presenc
receptor
block
antibodi
significantli
reduc
cell
treat
sarscov
pseudoviru
sera
highdos
siggtreat
macaqu
dilut
indic
antisarscov
antibodi
modifi
woundheal
respons
partial
figur
therefor
conclud
sigg
directli
modifi
function
respons
altern
activ
macrophag
acut
infect
thu
skew
woundheal
respons
lead
hypercytokinemia
aggress
inflamm
sever
lung
injuri
vitropolar
altern
activ
macrophag
either
left
unstimul
incub
sarscov
pseudoviru
alon
cocultur
sarscov
pseudoviru
dilut
sera
highdos
sigg
group
n
cigg
group
n
collect
dpi
healthi
macaqu
n
hour
secret
cytokin
chemokin
level
measur
cultur
supernat
shown
data
repres
column
graph
ad
fk
fold
percentag
supernat
macrophag
treat
viru
alon
e
l
show
level
supernat
classic
activ
altern
activ
mdm
treatment
b
c
show
sarscov
treatment
induc
low
level
product
altern
activ
mdm
well
enhanc
product
classic
activ
mdm
e
show
sera
sigg
recipi
caus
dosedepend
increas
cytokin
product
sarscovtr
altern
activ
mdm
fh
show
viru
treat
altern
activ
mdm
vt
sera
treat
untreat
cell
ut
secret
proinflammatori
cytokin
f
g
low
level
h
addit
sera
dilut
highdos
sigg
hst
cigg
treat
macaqu
ct
healthi
control
hct
significantli
amplifi
f
g
h
product
ik
show
addit
sera
dilut
highdos
siggtreat
hst
cigg
treat
macaqu
ct
healthi
control
hct
effect
j
k
product
sarscovtr
classic
activ
mdm
l
show
blockad
significantli
reduc
antiserumenhanc
secret
partial
reduc
secret
data
repres
mean
valu
mean
valu
sem
least
independ
experi
twotail
unpair
student
test
use
statist
analysi
p
p
p
p
examin
role
sigg
promot
ali
clinic
set
investig
antibodi
respons
earli
stage
infect
group
deceas
patient
individu
recov
sar
character
heterogen
monocyt
macrophag
lung
deceas
sar
patient
h
e
stain
lung
specimen
deriv
deceas
sar
patient
reveal
sever
ali
figur
consist
macaqu
find
ihc
analysi
reveal
signific
infiltr
monocytesmacrophag
lung
patient
littl
express
loss
woundheal
marker
indic
predominantli
proinflammatori
macrophag
activ
reduc
inflammatoryresolv
respons
figur
moreov
significantli
higher
level
anti
nab
detect
sera
deceas
patient
n
acut
infect
compar
recov
patient
n
figur
result
therefor
consist
find
experiment
macaqu
antisera
deceas
sar
patient
skew
woundheal
respons
sarscov
infect
partial
examin
whether
human
antisarscov
antibodi
modifi
woundheal
respons
sarscov
infect
treat
vitropolar
altern
activ
mdm
sarscov
pseudoviru
hour
presenc
sera
collect
sar
patient
acut
infect
macrophag
treat
sarscov
pseudoviru
sera
alon
includ
control
examin
protein
level
cytokineschemokin
cell
cultur
supernat
consist
find
macaqu
administr
sera
deceas
sar
patient
supplement
tabl
sarscovtr
altern
activ
mdm
caus
dosedepend
increas
product
cytokin
lead
increas
hour
figur
b
enhanc
howev
observ
cell
treat
sera
alon
figur
ad
administr
sera
recov
patient
n
supplement
tabl
effect
cytokin
product
except
sampl
figur
c
differ
may
explain
least
part
lower
nab
titer
although
also
possibl
sera
recov
patient
contain
differ
antibodi
popul
consist
serum
sampl
enhanc
chemokin
product
rel
higher
nab
titer
among
sampl
test
supplement
tabl
moreov
statist
analysi
show
product
strongli
correl
nab
titer
sera
deceas
patient
figur
furthermor
product
significantli
reduc
cell
treat
sarscov
pseudoviru
sera
deceas
sar
patient
dilut
presenc
block
antibodi
indic
antisarscov
antibodi
modifi
woundheal
respons
human
partial
figur
present
evid
detriment
role
antisigg
ali
sarscov
infect
respiratori
cov
infect
pose
uniqu
challeng
immun
system
must
viru
rapidli
elimin
lung
inflamm
must
also
control
prevent
acut
respiratori
failur
present
studi
show
despit
markedli
reduc
viru
titer
antisigg
caus
lung
injuri
earli
stage
infect
abrog
woundheal
macrophag
respons
product
promot
proinflammatori
cytokin
product
inflammatori
macrophag
accumul
knowledg
data
demonstr
previous
unrecogn
mechan
underli
virusmedi
ali
suggest
modul
anti
antibodi
respons
blockag
receptor
acut
infect
might
need
effect
treatment
respiratori
cov
infect
mani
studi
demonstr
role
nab
induc
glycoprotein
protect
viral
replic
suscept
host
includ
mice
ferret
hamster
macaqu
howev
effect
sspecif
immun
protect
pulmonari
immunopatholog
controversi
case
vaccinationinduc
immun
assist
viral
clearanc
protect
mice
ferret
lethal
challeng
wherea
mani
situat
multipl
vaccin
platform
appear
induc
increas
eosinophil
proinflammatori
pulmonari
respons
upon
challeng
differ
may
explain
part
characterist
vaccin
studi
infecti
dose
viral
strain
employ
well
type
qualiti
immun
respons
elicit
recent
studi
suggest
cell
respons
play
crucial
role
viral
clearanc
protect
mice
eosinophil
immunopatholog
lethal
sarscov
infect
wherea
immunopatholog
predominantli
reflect
inadequ
vaccineinduc
respons
fact
protect
effect
pulmonari
immunopatholog
mediat
full
length
proteinbas
vaccin
sarscovinfect
nonhuman
primat
model
describ
knowledg
although
sever
vaccin
candid
protect
macaqu
viral
replic
lung
pulmonari
immunopatholog
evalu
studi
contrast
shown
sarscovspecif
immun
memori
induc
prior
infect
enhanc
lung
inflamm
follow
homolog
challeng
african
green
monkey
similarli
augment
diseas
vaccin
also
describ
studi
atyp
measl
dengu
hemorrhag
fever
well
sever
respiratori
diseas
includ
respiratori
syncyti
viru
rsv
pandem
influenza
studi
rsv
vaccin
conduct
rsv
vaccine
need
hospit
wherea
rsvinfect
children
control
vaccin
group
requir
admiss
although
underli
mechan
remain
incomplet
understood
use
chines
rhesu
macaqu
show
adsmvabas
vaccin
protect
macaqu
viral
replic
significantli
enhanc
acut
dad
dpi
compar
control
adcmva
group
suggest
sspecif
mvaspecif
immun
promot
ali
figur
remain
unknown
sar
vaccin
candid
focu
receptorbind
domain
rbd
protein
avoid
induct
ali
nonhuman
primat
vaccin
shown
induc
highli
potent
nab
respons
elicit
longterm
protect
immun
immun
small
anim
sarscov
infect
chines
macaqu
often
character
rapid
control
viral
replic
mild
lung
lesion
macaqu
mechan
underli
chines
macaqu
often
develop
ali
observ
sar
patient
larg
unknown
data
suggest
effect
part
reflect
rapid
control
viral
replic
lung
peak
hour
inocul
hpi
diminish
within
day
thu
creat
interv
lung
inflamm
high
titer
antibodi
product
macaqu
inde
although
sarscov
infect
result
signific
infiltr
macrophag
lung
number
macrophag
rapidli
reduc
follow
viru
clearanc
dpi
figur
dpi
inflamm
appear
mostli
resolv
figur
contrast
control
viru
replic
less
effici
sar
patient
peak
viral
load
coincid
first
appear
antibodi
respons
approxim
day
onset
symptom
low
rate
ali
interv
lung
inflamm
resolut
antibodi
product
howev
make
chines
macaqu
ideal
anim
model
present
studi
use
vaccin
passiv
immun
condit
anti
antibodi
titer
macaqu
earli
stage
infect
ali
typic
observ
found
prior
administr
antisigg
led
massiv
accumul
monocytesmacrophag
lung
within
dpi
result
consist
previou
report
mice
given
sar
vaccin
exhibit
immunopatholog
lung
reaction
subsequ
challeng
sarscov
moreov
sar
patient
clinic
cours
outcom
favor
children
younger
year
age
compar
adolesc
adult
indic
prior
altern
cov
infect
might
play
role
drive
enhanc
pulmonari
inflamm
recent
studi
report
pathogen
immun
complex
promot
lung
injuri
pandem
remain
unknown
whether
immun
complex
may
also
play
role
drive
ali
sarscov
infect
detail
analys
macrophag
heterogen
differ
stage
infect
lung
sever
injuri
mild
lesion
reveal
distinct
role
proinflammatori
woundheal
macrophag
sar
diseas
progress
observ
earli
transit
macrophag
respons
proinflammatori
vitropolar
altern
activ
mdm
either
left
unstimul
incub
sarscov
pseudoviru
alon
cocultur
sarscov
pseudoviru
serial
dilut
dilut
sera
deceas
n
recov
sar
patient
n
hour
cell
treat
sera
patient
alon
serv
control
secret
cytokin
chemokin
level
measur
cultur
supernat
shown
data
repres
column
graph
c
fold
percentag
supernat
macrophag
treat
viru
alon
b
f
b
show
addit
sera
deceas
patient
dosedepend
enhanc
product
sarscovtr
altern
activ
mdm
c
show
significantli
enhanc
product
altern
activ
macrophag
treat
sera
deceas
sar
patient
viru
compar
cell
treat
viru
alon
sera
treatment
alon
induc
product
e
correl
product
nab
titer
sera
deceas
patient
solid
line
denot
relationship
histopatholog
score
serum
neutral
activ
f
blockad
human
significantli
reduc
antiserumenhanc
secret
partial
reduc
secret
vitropolar
altern
activ
human
monocytederiv
macrophag
cocultur
sarscov
pseudoviru
dilut
sera
deceas
patient
without
block
antibodi
hour
secret
cytokin
chemokin
level
measur
cultur
supernat
shown
data
repres
increas
supernat
macrophag
treat
viru
alon
data
repres
mean
valu
mean
valu
sem
least
independ
experi
twotail
unpair
student
test
spearman
rank
correl
test
use
statist
analysi
wound
heal
increas
express
associ
inflamm
resolut
mild
lung
injuri
contrast
abrog
wound
heal
sigg
result
decreas
product
prolong
classic
macrophag
activ
promot
sever
lung
injuri
find
primarili
base
imag
formalinfix
tissu
infect
macaqu
may
technic
limit
detail
flow
cytometr
analysi
would
help
character
macrophag
subpopul
infect
lung
unfortun
allow
obtain
live
cell
includ
macrophag
analysi
flow
cytometri
outsid
laboratori
china
line
biosafeti
guidelin
handl
sar
specimen
http
said
mainli
deriv
woundheal
macrophag
classic
activ
macrophag
therefor
stain
anoth
biomark
woundheal
macrophag
believ
find
reduct
type
macrophag
siggtreat
lung
convinc
patient
receiv
convalesc
plasma
recov
sar
patient
shorter
hospit
stay
lower
mortal
rate
without
evid
advers
effect
result
might
reflect
differ
qualiti
antibodi
recov
patient
deceas
patient
earli
infect
inde
previous
observ
deceas
patient
significantli
higher
nab
low
level
antin
antibodi
serum
earli
stage
infect
contrast
recov
patient
rapid
antin
antibodi
slower
nab
develop
consist
serum
deceas
patient
sar
survivor
earli
stage
infect
enhanc
product
woundheal
macrophag
figur
previous
identifi
epitop
protein
elicit
nab
antibodi
enhanc
sarscov
infect
studi
attempt
identifi
antibodi
epitop
mediat
prevent
enhanc
ali
might
need
futur
vaccin
design
immunotherapi
lastli
blockad
reduc
proinflammatori
cytokin
product
suggest
potenti
role
postul
reprogram
altern
activ
macrophag
function
divid
activ
inhibitori
receptor
activ
trigger
product
proinflammatori
chemokin
cytokin
immunoreceptor
tyrosinebas
activ
motif
itam
intracytoplasm
domain
src
famili
kinas
spleen
tyrosin
kinas
syk
wherea
inhibitori
immunoreceptor
tyrosinebas
inhi
bition
motif
itim
intracytoplasm
domain
counteract
signal
mediat
activ
base
literatur
experi
human
monocytederiv
woundheal
macrophag
express
higher
level
therefor
like
sigg
promot
proinflammatori
cytokin
product
andor
sigg
affect
classic
activ
macrophag
function
vitro
differ
possibl
explain
high
baselin
level
proinflammatori
cytokin
infect
downregul
express
classic
activ
mdm
sarscov
treatment
immun
anim
vaccin
chines
rhesu
macaqu
previous
describ
briefli
chines
rhesu
monkey
immun
twice
day
eight
anim
receiv
adsmva
wherea
anim
receiv
adcmva
adsmva
adcmva
vector
encod
sarscov
protein
hcv
construct
produc
previous
describ
dose
immun
tcid
vaccin
strain
sarscov
share
sequenc
homolog
gene
challeng
strain
sarscov
pumc
anim
tissu
sarscov
infect
sarscovinfect
anim
control
anim
adult
femal
chines
rhesu
macaqu
total
chines
rhesu
macaqu
challeng
live
pathogen
sarscov
pum
tcid
previous
describ
addit
uninfect
macaqu
inocul
pb
neg
control
anim
subject
daili
measur
anal
temperatur
routin
blood
assay
chest
radiographi
anim
euthan
day
inocul
figur
figur
figur
anim
human
euthan
iv
overdos
pentobarbit
immedi
necropsi
lung
tissu
left
right
cranial
middl
caudal
lobe
right
accessori
lobe
collect
fix
neutralbuff
formalin
embed
paraffin
section
passiv
transfer
igg
sarscov
proteinimmun
serum
gener
vaccin
adsmva
vector
igg
purifi
pool
sera
protein
g
affin
chromatographi
puriti
igg
depyrogen
concentr
mg
protein
ml
administ
iv
recipi
receiv
mg
mg
purifi
igg
per
kg
bodi
weight
hour
viral
challeng
neutral
assay
establish
determin
humor
immun
respons
gener
vaccin
previous
describ
neutral
activ
heatinactiv
anim
sera
determin
use
pseudotyp
viral
entri
assay
pseudotyp
viru
gener
cotransfect
cell
plasmid
carri
optim
gene
human
immunodefici
viru
type
backbon
respect
serial
dilut
serum
sampl
incub
equal
amount
pseudotyp
viru
hour
serumviru
mixtur
subsequ
ad
preseed
hek
cell
hour
infect
cell
lyse
measur
luciferas
activ
nest
rtpcr
isol
sarscov
pharyng
swab
sampl
collect
infect
monkey
first
day
inocul
subsequ
test
sarscov
use
nest
rtpcr
previous
describ
briefli
rna
isol
use
trizol
invitrogen
rtpcr
perform
reaction
volum
outer
primer
pair
inner
primer
pair
pcr
product
verifi
nucleotid
sequenc
sarscov
isol
previous
describ
briefli
pharyng
swab
sampl
infect
macaqu
inocul
onto
cell
cultur
dmem
thermo
fisher
scientif
cytopath
effect
cpe
immunofluoresc
assay
ifa
incub
dilut
sar
patient
serum
use
determin
infect
statu
anim
doubl
tripl
immunofluoresc
stain
paraffin
section
sampl
deparaffin
rehydr
block
normal
goat
serum
minut
room
temperatur
rabbit
antisarscov
nucleocapsid
antibodi
eenzym
appli
overnight
follow
alexa
fluor
conjug
goat
antirabbit
igg
antibodi
hour
room
temperatur
addit
immunofluoresc
stain
subsequ
perform
overnight
incub
primari
antibodi
follow
detect
signal
use
appropri
fluoresc
secondari
antibodi
milliporesigma
hour
room
temperatur
primari
antibodi
immunoflures
stain
follow
primari
antibodi
use
studi
sarscov
np
eenzym
clone
abd
serotec
clone
kpi
dako
abcam
clone
abd
abcam
clone
dako
milliporesigma
santa
cruz
biotechnolog
inc
santa
cruz
biotechnolog
inc
clone
dako
ish
studi
ish
develop
detect
sarscov
dna
fragment
n
protein
sarscov
strain
hong
kong
use
templat
gener
rna
probe
probe
label
digoxigenin
genewiz
inc
deparaffin
rehydr
section
treat
microwav
heat
w
domest
microwav
oven
panason
medium
power
minut
sodium
citrat
buffer
hybrid
perform
high
stringenc
ngml
denatur
probe
hour
hybrid
mix
formamid
dextran
sulfat
salin
sodium
citrat
ssc
moist
chamber
excess
probe
remov
wash
twice
ssc
minut
follow
wash
ssc
ssc
minut
immunolog
detect
conduct
use
dig
nuclear
acid
detect
kit
roch
diagnost
accord
manufactur
instruct
briefli
incub
block
reagent
minut
section
incub
sheep
antidigoxigenin
alkalin
phosphatas
conjug
roch
diagnost
dilut
hour
room
temperatur
separ
wash
wash
buffer
maleic
acid
nacl
ph
tween
signal
develop
use
hnppfast
red
tr
mix
roch
diagnost
dark
minut
section
counterstain
dapi
tissu
section
incub
sens
rna
probe
use
neg
control
confoc
microscopi
confoc
microscopi
perform
use
carl
zeiss
lsm
confoc
microscop
equip
laser
zeiss
zen
zeiss
use
assign
color
channel
collect
alexa
fluor
hnppfast
red
fluoresc
expos
wavelength
laser
appear
red
alexa
fluor
molecular
probe
appear
green
alexa
fluor
molecular
probe
appear
cyan
differenti
interfer
contrast
dic
imag
gray
scale
channel
simultan
collect
differenti
individu
cell
hoechst
nuclear
marker
molecular
probe
use
incub
minut
follow
rins
water
coloc
antigen
demonstr
addit
color
indic
figur
legend
monocyt
isol
differenti
polar
macrophag
monocyt
purifi
peripher
blood
mononuclear
cell
obtain
blood
buffi
coat
provid
red
cross
hong
kong
china
monkey
peripher
blood
previous
describ
monkey
peripher
blood
obtain
heparin
vacutain
collect
tube
healthi
femal
rhesu
monkey
gener
macrophag
monocyt
differenti
rpmi
medium
thermo
fisher
scientif
supplement
gmcsf
iuml
mm
glutamin
decompl
fc
iu
ml
penicillin
streptomycin
thermo
fisher
scientif
day
follow
exposur
fresh
medium
supplement
fc
contain
gmcsf
lp
ngml
ngml
addit
hour
gener
macrophag
monocyt
differenti
rpmi
medium
thermo
fisher
scientif
supplement
mcsf
ngml
mm
glutamin
decompl
fc
iuml
penicillin
streptomycin
day
follow
exposur
fresh
medium
supplement
fc
contain
mcsf
ngml
ngml
addit
hour
quantif
cytokin
level
panel
cytokin
includ
monkey
sera
cultur
medium
quantifi
use
multiplex
laser
bead
technolog
biolegend
assess
cytokin
product
macrophag
vitropolar
cell
wash
time
pb
subsequ
activ
sarscov
pseudotyp
viru
rpmi
medium
thermo
fisher
scientif
without
administr
highli
dilut
heatinactiv
sera
macaqu
sar
patient
mous
monoclon
antibodi
clone
clone
clone
bd
pharmingen
use
blockad
human
supernat
cultur
recov
hour
stimul
cytokin
level
measur
analyz
statist
statist
analys
perform
use
student
test
p
valu
less
consid
statist
signific
data
present
mean
valu
sem
least
independ
experi
unless
otherwis
indic
studi
approv
experi
conduct
biosafeti
level
anim
facil
handl
experiment
procedur
includ
inject
blood
collect
viru
challeng
sacrif
approv
perform
accord
anim
welfar
committe
use
live
anim
teach
research
institut
laboratori
anim
scienc
beij
china
studi
subject
gave
inform
consent
procedur
review
approv
univers
hong
kong
research
ethic
committe
zc
qw
design
studi
qw
analyz
data
zc
kyy
sp
al
contribut
draft
manuscript
zc
princip
investig
overal
respons
design
studi
qw
cq
coordin
autopsi
organ
collect
autopsi
materi
chines
macaqu
qw
involv
develop
perform
rtpcr
assay
ht
tw
kwc
perform
neutral
assay
xa
al
involv
develop
h
e
sarscov
ihc
ish
assay
hw
perform
ish
assay
ihc
stain
np
calcul
mean
floresc
intens
lung
hk
kn
perform
h
e
doubleor
tripleihc
stain
jf
ht
perform
cultur
monocytederiv
macrophag
ql
ht
jp
zt
perform
analysi
cytokin
product
cell
cultur
supernat
monkey
sera
khc
kyy
coordin
collect
sera
tissu
sampl
sar
patient
author
involv
correl
interpret
patholog
molecular
data
